Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Paz-Ares L, et al. Among authors: peterson pm. J Clin Oncol. 2006 Mar 20;24(9):1428-34. doi: 10.1200/JCO.2005.04.3299. J Clin Oncol. 2006. PMID: 16549837 Clinical Trial.
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L. Scagliotti GV, et al. Among authors: peterson pm. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):690-6. Clin Cancer Res. 2005. PMID: 15701857 Clinical Trial.
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Free article. Clinical Trial.
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P. Scagliotti GV, et al. Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25. Eur J Cancer. 2009. PMID: 19473833 Clinical Trial.
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Ciuleanu T, et al. Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767093 Clinical Trial.
91 results